search
Back to results

Study to Assess the Effects of Non Digestible Carbohydrates on Long-Term Glucose Homeostasis in Untreated Prediabetic Subjects (FOS_GLUCOSE)

Primary Purpose

Pre Diabetes, Prediabetic State, Dysglycemia

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Non digestible carbohydrates
Placebo
Sponsored by
Tereos
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pre Diabetes

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age between 18 and 65 years (limits included);
  • BMI between 25 and 34.9 kg/m² (limits included);
  • Dysglycemic or prediabetic subjects with no antidiabetic medication (medical or lifestyle (hygiene-dietetic measures or specific regimen treatment);
  • Consuming 10 to 20 g quantity of fiber per day (based on the 3-days food diary fulfilled by the subject between V1 and V2 visits);
  • Non smoking subject and agreeing to keep this habit unchanged throughout the study;
  • Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form;
  • Affiliated with a social security scheme;
  • Agree to be registered on the volunteers in biomedical research file;
  • Fasting venous glycemia ≥ 1 g/L and ≤ 1.25 g/L at V1 visit.

Exclusion Criteria:

  • Metabolic disorder such as diabetes, uncontrolled thyroidal trouble or other metabolic disorder;
  • Severe chronic disease or Intestinal Bowel Syndrome (IBS) or gastrointestinal disorders found to be inconsistent with the conduct of the study by the investigator;
  • History of retinopathy, microalbuminuria, ischemic cardiovascular event in the 6 months before the study;
  • Known or a suspected food allergy or intolerance orhypersensitivity to any food ingredient;
  • Known or suspected food allergy or intolerance or hypersensitivity to any of the study products' ingredient;
  • Pregnant or lactating women or intending to become pregnant within 4 months ahead;
  • Women starting hormone replacement therapy or oral contraception (treatment must be stable for at least 3 months);
  • History of bariatric surgery;
  • History of any surgery in the 3 months before V1 visit or having scheduled any surgery within 4 months ahead;
  • Under dietary supplement which could significantly affect parameter(s) followed during the study according to the investigator or stopped in a too short period before the V1 visit (< 3 months);
  • Under treatment which could significantly affect parameter(s) followed during the study according to the investigator or stopped less than 3 months before the V1 visit;
  • Under antibiotic treatment in the 3 to 6 months before V1 visit, depending on the antibiotic consumed and according to the investigator;
  • Significant change in food habits or in physical activity in the 3 months before V1 visit or not agreeing to keep them unchanged throughout the study;
  • Current or planned in the next 4 months specific diet (hyper or hypocaloric, vegan, vegetarian…) or stopped less than 3 months before the study;
  • Personal history of anorexia nervosa, bulimia or significant eatingdisorders according to the investigator;
  • Consuming more than 3 standard drinks of alcoholic beverage daily for men or 2 daily for women or not agreeing to keep his alcohol consumption habits unchanged throughout the study;
  • Taking part in another clinical trial or being in the exclusion period of a previous clinical trial;
  • Having received, during the last 12 months, indemnities for clinical trial higher or equal to 4500 Euros;
  • Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision;
  • Psychological or linguistic incapability to sign the informed consent;
  • Impossible to contact in case of emergency.
  • Fasting blood triglycerides > 3,5 g/L;
  • Fasting blood of total cholesterol > 4,5 g/L or HDLc < 0,1 g/L with an abnormality judged as clinically significant according to the investigator;
  • Blood ASAT, ALAT or GGT > 3 times ULN (laboratory Upper Limit of Normal);
  • Blood urea > 12 mmol/L or creatinine > 125 μmol/L;
  • Complete Blood Count (CBC) with hemoglobin < 11 g/L or leucocytes < 3000/mm3 or leucocytes > 16000/mm3.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Test product

    Placebo

    Arm Description

    Food ingredient containing non digestible carbohydrates, in shape of powder

    Food ingredient containing containing 95% of maltodextrin

    Outcomes

    Primary Outcome Measures

    Glycated hemoglobin
    Change from baseline of Hba1c level (%)

    Secondary Outcome Measures

    Glycated hemoglobin
    Absolute variations of Hba1c level (%)
    Fasting glycemia
    Change from baseline of fasting glycemia (g/L)
    Fasting insulinemia
    Change from baseline of fasting insulinemia (mU/L)
    Fructosamine
    Change from baseline of fructosamine (μmol/L)
    Insulin indexes
    Change from baseline of HOMA-IR (Homeostasis Model Assessment of Insulin) and QUICKI (Quantitative Insulin sensitivity Check Index) indices
    Insulin sensitivity index
    Change from baseline of insulin sensitivity index (ISI)
    Glycemia level
    Change from baseline of glycemia level (g/L)
    Incremental Area Under the Curve (iAUC) of glycemia
    Change from baseline of iAUC of glycemia (g/L)
    Insulinemia
    Change from baseline of insulinemia levels (mU/L)
    Incremental Area Under the Curve (iAUC) of insulinemia
    Change from baseline of iAUC of insulinemia (mU/L)
    Glucacon-like Peptide 1 (GLP-1)
    Change from baseline of GLP-1 levels (pmol/L)
    Bone mineral composition
    Change from baseline of bone mineral composition (kg)
    Total lean mass
    Change from baseline of total lean mass (g and %)
    Total fat mass
    Change from baseline of total fat mass (g and %)
    Bone Mineral Density
    Change from baseline of bone mineral density (g/cm2)
    Total Body Mass
    Change from baseline of total body mass (kg)
    Weight
    Change from baseline of weight (in kg)
    Body Mass Index (BMI)
    Change from baseline of BMI (in kg/m2)
    Waist and Hip measurement
    Change from baseline of waist and hip Circumference (in cm)
    Anthropometric ratios
    Change from baseline of Waist to Hip ratio and Waist to Height ratio
    Satiety and Appetite sensation
    Change on satiety and appetite sensation using 100-mm VAS to complete 15 min before the meal, 30 min, 60 min, 120 min, 180 min and 240 min after the meal at which study product was consumed
    Total energy intake
    Change from baseline of total energy intake - TEI (kcal/day)
    Energy intake
    Change from baseline of percentage of energy intake from fat, carbohydrates and protein (g and %TEI)
    Fiber intake
    Change from baseline of percentage of percentage of fiber (g)
    Alcohol intake
    Change from baseline of percentage of percentage of alcohol intake (absolute quantities, g/day)
    Biomarker of inflammation
    Change from baseline of high-sensitivity C-reactive Protein (CRPhs) (mg/L)
    Intestinal microbiota composition
    Change from baseline microbiota composition for alpha-diversity indices (Shannon and Chao indices) and abundances at the phylum, family and genus level assessed by 16S metabarcoding (in a subgroup of 30 subjects only)
    Fecal Short-Chain Fatty Acids (SCFA)
    Change from baseline of fermentative activity of the intestinal microbiota assessed by measuring short-chain fatty acids concentrations in stool (in the same subgroup of 30 subjects only)

    Full Information

    First Posted
    February 19, 2021
    Last Updated
    March 11, 2021
    Sponsor
    Tereos
    Collaborators
    Biofortis, Merieux NutriSciences
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04767672
    Brief Title
    Study to Assess the Effects of Non Digestible Carbohydrates on Long-Term Glucose Homeostasis in Untreated Prediabetic Subjects
    Acronym
    FOS_GLUCOSE
    Official Title
    Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Effects of Short-Chain Fructo-Oligosaccharides on Long-Term Glucose Homeostasis in Untreated Prediabetic Subjects
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2021
    Overall Recruitment Status
    Unknown status
    Study Start Date
    March 2021 (Anticipated)
    Primary Completion Date
    July 2023 (Anticipated)
    Study Completion Date
    July 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Tereos
    Collaborators
    Biofortis, Merieux NutriSciences

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This clinical study aims to prove that the efficacy of non digestible carbohydrates supplementation (daily dose of 20 grams consumed twice a day for 12 weeks) on the regulation of glucose homeostasis is superior than placebo in prediabetic subjects.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pre Diabetes, Prediabetic State, Dysglycemia, PreDiabetes

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    multicentre randomized, parallel arms, double-blind, placebo-controlled clinical trial
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    70 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Test product
    Arm Type
    Experimental
    Arm Description
    Food ingredient containing non digestible carbohydrates, in shape of powder
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Food ingredient containing containing 95% of maltodextrin
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Non digestible carbohydrates
    Intervention Description
    the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Placebo
    Intervention Description
    the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
    Primary Outcome Measure Information:
    Title
    Glycated hemoglobin
    Description
    Change from baseline of Hba1c level (%)
    Time Frame
    V2 (randomization) and V5 (12 weeks of intervention)
    Secondary Outcome Measure Information:
    Title
    Glycated hemoglobin
    Description
    Absolute variations of Hba1c level (%)
    Time Frame
    V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
    Title
    Fasting glycemia
    Description
    Change from baseline of fasting glycemia (g/L)
    Time Frame
    V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
    Title
    Fasting insulinemia
    Description
    Change from baseline of fasting insulinemia (mU/L)
    Time Frame
    V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
    Title
    Fructosamine
    Description
    Change from baseline of fructosamine (μmol/L)
    Time Frame
    V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
    Title
    Insulin indexes
    Description
    Change from baseline of HOMA-IR (Homeostasis Model Assessment of Insulin) and QUICKI (Quantitative Insulin sensitivity Check Index) indices
    Time Frame
    V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
    Title
    Insulin sensitivity index
    Description
    Change from baseline of insulin sensitivity index (ISI)
    Time Frame
    V2 (randomization) and V5 (12 weeks of intervention)
    Title
    Glycemia level
    Description
    Change from baseline of glycemia level (g/L)
    Time Frame
    V2 (randomization) and V5 (12 weeks of intervention)
    Title
    Incremental Area Under the Curve (iAUC) of glycemia
    Description
    Change from baseline of iAUC of glycemia (g/L)
    Time Frame
    V2 (randomization) and V5 (12 weeks of intervention)
    Title
    Insulinemia
    Description
    Change from baseline of insulinemia levels (mU/L)
    Time Frame
    V2 (randomization) and V5 (12 weeks of intervention)
    Title
    Incremental Area Under the Curve (iAUC) of insulinemia
    Description
    Change from baseline of iAUC of insulinemia (mU/L)
    Time Frame
    V2 (randomization) and V5 (12 weeks of intervention)
    Title
    Glucacon-like Peptide 1 (GLP-1)
    Description
    Change from baseline of GLP-1 levels (pmol/L)
    Time Frame
    V2 (randomization) and V5 (12 weeks of intervention)
    Title
    Bone mineral composition
    Description
    Change from baseline of bone mineral composition (kg)
    Time Frame
    V2 (randomization) and V5 (12 weeks of intervention)
    Title
    Total lean mass
    Description
    Change from baseline of total lean mass (g and %)
    Time Frame
    V2 (randomization) and V5 (12 weeks of intervention)
    Title
    Total fat mass
    Description
    Change from baseline of total fat mass (g and %)
    Time Frame
    V2 (randomization) and V5 (12 weeks of intervention)
    Title
    Bone Mineral Density
    Description
    Change from baseline of bone mineral density (g/cm2)
    Time Frame
    V2 (randomization) and V5 (12 weeks of intervention)
    Title
    Total Body Mass
    Description
    Change from baseline of total body mass (kg)
    Time Frame
    V2 (randomization) and V5 (12 weeks of intervention)
    Title
    Weight
    Description
    Change from baseline of weight (in kg)
    Time Frame
    V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
    Title
    Body Mass Index (BMI)
    Description
    Change from baseline of BMI (in kg/m2)
    Time Frame
    V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
    Title
    Waist and Hip measurement
    Description
    Change from baseline of waist and hip Circumference (in cm)
    Time Frame
    V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
    Title
    Anthropometric ratios
    Description
    Change from baseline of Waist to Hip ratio and Waist to Height ratio
    Time Frame
    V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
    Title
    Satiety and Appetite sensation
    Description
    Change on satiety and appetite sensation using 100-mm VAS to complete 15 min before the meal, 30 min, 60 min, 120 min, 180 min and 240 min after the meal at which study product was consumed
    Time Frame
    V2 (randomization) and V5 (12 weeks of intervention)
    Title
    Total energy intake
    Description
    Change from baseline of total energy intake - TEI (kcal/day)
    Time Frame
    V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
    Title
    Energy intake
    Description
    Change from baseline of percentage of energy intake from fat, carbohydrates and protein (g and %TEI)
    Time Frame
    V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
    Title
    Fiber intake
    Description
    Change from baseline of percentage of percentage of fiber (g)
    Time Frame
    V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
    Title
    Alcohol intake
    Description
    Change from baseline of percentage of percentage of alcohol intake (absolute quantities, g/day)
    Time Frame
    V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
    Title
    Biomarker of inflammation
    Description
    Change from baseline of high-sensitivity C-reactive Protein (CRPhs) (mg/L)
    Time Frame
    V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
    Title
    Intestinal microbiota composition
    Description
    Change from baseline microbiota composition for alpha-diversity indices (Shannon and Chao indices) and abundances at the phylum, family and genus level assessed by 16S metabarcoding (in a subgroup of 30 subjects only)
    Time Frame
    V2 (randomization) and V5 (12 weeks of intervention)
    Title
    Fecal Short-Chain Fatty Acids (SCFA)
    Description
    Change from baseline of fermentative activity of the intestinal microbiota assessed by measuring short-chain fatty acids concentrations in stool (in the same subgroup of 30 subjects only)
    Time Frame
    V2 (randomization) and V5 (12 weeks of intervention)
    Other Pre-specified Outcome Measures:
    Title
    Incidence of adverse events (AEs)
    Description
    Number of adverse events (including gastro-intestinal symptoms) by subject that appeared during the entire duration of the study
    Time Frame
    V1 (Inclusion), V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
    Title
    Heart Rate (HR)
    Description
    Change from baseline of HR (bpm)
    Time Frame
    V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
    Title
    Blood pressure
    Description
    Change from baseline of Systolic Blood Pressure and Diastolic Blood Pressure (mmHg)
    Time Frame
    V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age between 18 and 65 years (limits included); BMI between 25 and 34.9 kg/m² (limits included); Dysglycemic or prediabetic subjects with no antidiabetic medication (medical or lifestyle (hygiene-dietetic measures or specific regimen treatment); Consuming 10 to 20 g quantity of fiber per day (based on the 3-days food diary fulfilled by the subject between V1 and V2 visits); Non smoking subject and agreeing to keep this habit unchanged throughout the study; Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form; Affiliated with a social security scheme; Agree to be registered on the volunteers in biomedical research file; Fasting venous glycemia ≥ 1 g/L and ≤ 1.25 g/L at V1 visit. Exclusion Criteria: Metabolic disorder such as diabetes, uncontrolled thyroidal trouble or other metabolic disorder; Severe chronic disease or Intestinal Bowel Syndrome (IBS) or gastrointestinal disorders found to be inconsistent with the conduct of the study by the investigator; History of retinopathy, microalbuminuria, ischemic cardiovascular event in the 6 months before the study; Known or a suspected food allergy or intolerance orhypersensitivity to any food ingredient; Known or suspected food allergy or intolerance or hypersensitivity to any of the study products' ingredient; Pregnant or lactating women or intending to become pregnant within 4 months ahead; Women starting hormone replacement therapy or oral contraception (treatment must be stable for at least 3 months); History of bariatric surgery; History of any surgery in the 3 months before V1 visit or having scheduled any surgery within 4 months ahead; Under dietary supplement which could significantly affect parameter(s) followed during the study according to the investigator or stopped in a too short period before the V1 visit (< 3 months); Under treatment which could significantly affect parameter(s) followed during the study according to the investigator or stopped less than 3 months before the V1 visit; Under antibiotic treatment in the 3 to 6 months before V1 visit, depending on the antibiotic consumed and according to the investigator; Significant change in food habits or in physical activity in the 3 months before V1 visit or not agreeing to keep them unchanged throughout the study; Current or planned in the next 4 months specific diet (hyper or hypocaloric, vegan, vegetarian…) or stopped less than 3 months before the study; Personal history of anorexia nervosa, bulimia or significant eatingdisorders according to the investigator; Consuming more than 3 standard drinks of alcoholic beverage daily for men or 2 daily for women or not agreeing to keep his alcohol consumption habits unchanged throughout the study; Taking part in another clinical trial or being in the exclusion period of a previous clinical trial; Having received, during the last 12 months, indemnities for clinical trial higher or equal to 4500 Euros; Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision; Psychological or linguistic incapability to sign the informed consent; Impossible to contact in case of emergency. Fasting blood triglycerides > 3,5 g/L; Fasting blood of total cholesterol > 4,5 g/L or HDLc < 0,1 g/L with an abnormality judged as clinically significant according to the investigator; Blood ASAT, ALAT or GGT > 3 times ULN (laboratory Upper Limit of Normal); Blood urea > 12 mmol/L or creatinine > 125 μmol/L; Complete Blood Count (CBC) with hemoglobin < 11 g/L or leucocytes < 3000/mm3 or leucocytes > 16000/mm3.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Marion LIGNER
    Phone
    0240205799
    Email
    marion.ligner@mxns.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Biofortis Nutrisciences
    Phone
    0240205799
    Email
    fosglucose-study_oc@mxns.com

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Study to Assess the Effects of Non Digestible Carbohydrates on Long-Term Glucose Homeostasis in Untreated Prediabetic Subjects

    We'll reach out to this number within 24 hrs